Drug General Information
Drug ID	D06EGV
Former ID	DNCL003806
Drug Name	LY2801653
Drug Type	Small molecular drug
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 2	[523337]
Company	Lilly
Structure		Download 2D MOL 3D MOL
Formula	C30H22F2N6O3
PubChem Compound ID	44603533
Target and Pathway
Target(s)	Hepatocyte growth factor receptor	Target Info	Modulator	[532170], [551095]
KEGG Pathway	Ras signaling pathway
	Rap1 signaling pathway
	Cytokine-cytokine receptor interaction
	Endocytosis
	PI3K-Akt signaling pathway
	Axon guidance
	Focal adhesion
	Adherens junction
	Bacterial invasion of epithelial cells
	Epithelial cell signaling in Helicobacter pylori infection
	Malaria
	Pathways in cancer
	Transcriptional misregulation in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Renal cell carcinoma
	Melanoma
	Central carbon metabolism in cancer
Pathway Interaction Database	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
	Arf6 signaling events
	Signaling events mediated by TCPTP
	Posttranslational regulation of adherens junction stability and dissassembly
	Direct p53 effectors
	Syndecan-1-mediated signaling events
	Stabilization and expansion of the E-cadherin adherens junction
	a6b1 and a6b4 Integrin signaling
	FGF signaling pathway
	Regulation of retinoblastoma protein
Reactome	Sema4D mediated inhibition of cell attachment and migration
WikiPathways	TGF beta Signaling Pathway
	Signaling of Hepatocyte Growth Factor Receptor
	Focal Adhesion
	Extracellular vesicle-mediated signaling in recipient cells
	Signaling Pathways in Glioblastoma
	miR-targeted genes in squamous cell - TarBase
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	Semaphorin interactions
References
Ref 523337	ClinicalTrials.gov (NCT01285037) A Study of LY2801653 in Advanced Cancer. U.S. National Institutes of Health.
Ref 532170	LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44.
Ref 551095	Clinical pipeline report, company report or official report of Eli Lilly.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.